Longer FVIII: The 4th generation

Blood

Volumn 119, Issue 13, 2012, Pages 2972-2973

  Makris, Michael ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; ETANERCEPT; HUMAN ALBUMIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; RECOMBINANT BLOOD CLOTTING FACTOR 8; ROMIPLOSTIM; VON WILLEBRAND FACTOR;

BLOOD TRANSFUSION; CELL SURFACE; CIRCULATION; DRUG EFFICACY; DRUG HALF LIFE; ENDOCYTOSIS; GLOMERULUS FILTRATION; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; LIFE EXPECTANCY; LIVER CELL; LYSOSOME; MORBIDITY; NONHUMAN; NOTE; PARTIAL THROMBOPLASTIN TIME; PINOCYTOSIS; PRIORITY JOURNAL;

EID: 84859198466     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403675     Document Type: Note

References (5)

1. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophiliaApatients. Blood. 2012;119(13):3031-3037.
2. Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008;99(5):840-850. (Pubitemid 351705300)
3. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in haemophilia B patients. Blood. 2012;119(3):666-672.
4. Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012;119(13):3024-3030.
5. Terraube V, O'Donnel JS, Jenkins PV. Factor VIII and von Willebrand factor interaction; biological, clinical and therapeutic importance. Haemophilia. 2010;16(1):3-13.